Occurrence of a myelodysplastic syndrome (MDS) during first-line 2-chloro-deoxyadenosine (2-CDA) treatment of a low-grade gastrointestinal MALT lymphoma. Case report and review of the literature.
Occurrence of a myelodysplastic syndrome (MDS) during first-line 2-chloro-deoxyadenosine (2-CDA) treatment of a low-grade gastrointestinal MALT lymphoma. Case report and review of the literature.
复制标题
一线 2-氯脱氧腺苷 (2-CDA) 治疗低度胃肠道 MALT 淋巴瘤期间出现骨髓增生异常综合征 (MDS)。
作者：
G. Jäger;G. Höfler;W. Linkesch;P. Neumeister
虽然骨髓增生异常综合征（MDS）和急性白血病（AL）是化疗后众所周知的继发性疾病，特别是烷化剂，但在嘌呤类似物治疗的背景下很少报告。在所有病例中，继发性疾病发作前间隔数月，细胞遗传学分析显示典型的染色体畸变。我们报告的情况下，68岁的男性白人与低度恶性淋巴瘤谁开发的MDS正在进行的一线治疗嘌呤类似物2-CDA（克拉屈滨）。此外，最初和所有连续对照评价时均存在正常核型。因此，该病例代表了嘌呤类似物治疗相关MDS演变的另一种罕见报告;细胞遗传学畸变的缺失可能表明这种继发性疾病的发病机制不同。
While myelodysplastic syndrome (MDS) and acute leukemia (AL) are well-known secondary diseases after administration of chemotherapy, particularly alkylating agents, they have only rarely been reported in the context of purine analog treatment. In all cases there was an interval of several months before onset of the secondary disease and cytogenetic analyses showed typical chromosomal aberrations. We report the case of a 68-year old male Caucasian with low-grade lymphoma who developed a MDS during ongoing first-line treatment with the purine analog 2-CDA (Cladribine). Furthermore, a normal karyotype was present initially and at all consecutive control evaluations. Thus, this case represents another rare report of an evolution of purine analog treatment-associated MDS; the absence of cytogenetic aberrations might suggest a different mechanism in the pathogenesis of this secondary disease.